Advancements in Gene Therapy, Synthetic

Biology, Diagnostic Assays, Imaging Tracers, and

Biopharma--Life Sciences, Health & Wellness
TechVision Opportunity Engine

TechVision Group of Frost & Sullivan

D759-TV
January 18, 2019

© 2019 Frost & Sullivan. All rights reserved. This document contains confidential information and is the sole property of Frost & Sullivan.
No part of it may be circulated, quoted, copied or otherwise reproduced without the written approval of Frost & Sullivan.
Table of Contents
Powerful topics in life sciences

Growth Opportunities in Life Sciences – Health & Wellness

Exploring the Potential of Novel Platforms in Life Sciences 3

Exploring the Potential of Novel Platforms in Life Sciences - 12 Disruptive Life Sciences Stories 4
Cloud-based Molecular Modeling and Protein Design 5
On/Off Switches for Genetically Modified Organisms 6
On-Point Solutions for a Smart Lab 7
Extremozymes for Therapeutics Development 8
Leveraging Human Data Science and Advanced Analytics for Clinical Genomics 9
Leveraging Homologous Recombination for Gene Editing 10
Advancing the Manufacture of Viral Vectors 11
Accelerating the Development of Biopharmaceutical Products 12
Promising Preclinical Data for an off-the-shelf Cell Therapy 13

Tau PET Imaging Tracer, APN-1607 Licensed for use in Tauopathy Clinical Studies 14
Prognostic and Diagnostic Cancer Screening Assays 15
®
Encouraging Interim Clinical Results of GoCAR-T Cell Therapy Candidate 16
Industry Relations 17
 Exploring the Potential of Novel Platforms in Life
Sciences

D759-TV 3
Exploring the Potential of Novel Platforms in Life Sciences
Growth Opportunities in Life Sciences Research

1
Cyrus Bench™
12 Cyrus
Controllable Biotechnology 2
CAR-T On/Off Synbio
candidate Switches
11
Cancer Bellicum Synvivia 3
Screening Pharma On-Point
Assays Solutions
Contextual Elemental
Genomics Machines

10
Tau Imaging 12
Tracer Disruptive 4
APRINOIA Life Sciences Extremozymes
Therapeutics Stories iXpressGenes

9
Allogenic Cell
Therapy 5
Fate IQVIA CORE
Therapeutics 8 6 IQVIA
Biopharma Homologous
Development Recombination
Batavia Homology
7
Synthetic Biology Biosciences Viral Vector Medicines

Groundbreaking CDMOs Manufacture

Vigene
Advanced diagnostic tools Biosciences Source: Frost & Sullivan
Cloud-based Molecular Modeling and Protein Design
Cyrus Biotechnology, Seattle, WA, US

Cyrus Bench™: The best suited Rosetta’s version

Cyrus’ powerful software tool to address protein structure prediction, molecular modeling, and protein design on the cloud

Cyrus Bench™ Software Cloud-based Access Competitive Attributes Business Development

Cyrus Biotechnology Cyrus Bench can be Cyrus Bench comprises an Cyrus partners with Fortune
launched Cyrus Bench, a accessed on the cloud, optimal array of molecular 500 pharmaceutical firms,
modern version of the well- where Rosetta’s capabilities modeling software, including 10 of the top 20
proven Rosetta molecular are provided completely, including sequence and companies. Cyrus also
modeling and protein design including the associated structure alignment. provides technologies for mid-
software package. array of bio-molecular Protein modeling, which sized biotechnology firms and
Cyrus Bench leverages computation tools. conventionally requires tens startups.
Rosetta’s powerful protein Cyrus developed a custom- or hundreds of thousands of Among the well-renowned
structure prediction, designed Rosetta’s graphical computational processors, customers, Cyrus provides
computational protein design, user interface (GUI) to enable are accessible on the cloud. support to Janssen
protein binders, and the automated attachment of Workflow is intuitive, Pharmaceuticals, BASF,
antibody-like affinity different sets of standard automated, and simplified. Illumina, and Harvard Medical
modeling. user procedures. School.

Source: Frost & Sullivan

5
On/Off Switches for Genetically Modified Organisms
Synvivia, Berkeley, CA, US

On/Off Switches Rationale

• Synvivia excels in the synthetic biology space with the • Synvivia’s genetically encoded biocontainment system uses
development of organisms capable of being controlled via small programmable, self-replicating, engineered organisms to be
molecules. applied across many industries and sectors such as life
• Organisms’ cells can be either On or Off; the small molecule science therapeutics and diagnostics, advanced agriculture,
based control system decides about the organism activity by and molecular chemistry.
switching these binary parameters. • Synvivia’s technology makes use of synthetic biology by
• These On/Off switches are installed in the organism, so that facilitating the growth, spread, and modification of the
Synvivia can engineer these organisms to facilitate their control environment, taking into consideration all potential risks.
by using small molecules. • While natural organisms have evolved over billions of years,
• This technology is based on Synvivia’s lead product, a synthetic organisms are relatively new. Hence, synthetic
genetically encoded biocontainment system that can be applied organisms must be strictly controlled outside the lab.
to therapeutic organisms.
Technology Transfer
Commercially Available Synthetic Biology Developed at UC Berkeley and financially supported by NSF and
DARPA, Synvivia's technology has found a market niche for its
commercial synthetic biology product.
Synvivia launched the first Synvivia emphasizes the
commercially available relevance of developing Business Model
genetically encoded high-performance control • Synvivia holds the exclusive license for this technology to be
biocontainment system. This systems in genetically applied in all fields. Synvivia is applying for funding to Y
system enables organism engineered organisms to Combinator and the National Institutes of Health, to optimize the
control through specific small guarantee the safe use of market penetration of its genetically encoded biocontainment
molecules, especially designed synthetic biology outside of technology to diversify it in a complete suite of products.
by Synvivia. the laboratory.
Source: Frost & Sullivan

6
On-Point Solutions for a Smart Lab
Elemental Machines, Salem, New Hampshire, US

Artificial Intelligence (AI) meets life sciences by introducing the concept of ‘smart lab’.
Elemental Machines provides on-point solutions to achieve this goal by leveraging AI-based technology
platforms to enhance pre-clinical outcomes and laboratory compliance.

Impact on Connected Solutions Impact on Data Analytics

Elemental Machines provides a complete suite of on-point
solutions based on three main technology approaches:
• Cloud connected sensors seamlessly carry out critical
parameter monitoring to enhance pre-clinical outcomes.
• Internet-of-Things (IoT) equipment automatically streams data
from instruments to a cloud repository for instant access.
• Cloud-based storage for easy, safe shared access to the
complete set of data.
Elemental Machines exploits the data analytics platform to
provide optimal solutions regarding:
• Predictive analytics to effectively track the proper functioning
of instruments and sensors to prevent failures early.
• Utilization effectiveness to optimize the use and replacement
of equipment.
• AI-based analytics to discover non-trivially related factors and
provide effective research results.

Impact on AI-based Infrastructure Impact on Compliance

• Elemental Machines’ platform empowers its customers with
AI-based infrastructure with the aim to improve both R&D lab
outcomes and biotechnology manufacturing processes. Lab
protocols can be optimized, while lab conditions, equipment
performance, and production yield can be enhanced.
• Elemental Machines’ AI-based technology comprises credit-
card-sized smart sensors, wireless devices, intelligent read-
out displays, as well as, intuitive Web-based dashboards and
software predicting tools for visualization and advanced
analytics.
• Unique user log ins are used for secure data storage and
master control access, hence facilitating quality and regulatory
compliance such as 21 CFR Part 11.
According to Frost & Sullivan’s analysis, Elemental
Machines brings significant advantages for life science
organizations, especially regarding R&D process
optimization, biomanufacturing equipment, and regulatory
compliance.

Source: Frost & Sullivan

7
Extremozymes for Therapeutics Development
iXpressGenes, Huntsville, AL, US

iXpressGenes is a synthetic biology company located at the HudsonAlpha Institute for Biotechnology, focused on
protein and genetic engineering research in extreme conditions.
Seeing Beyond the Ecosystem

Deep Sea
(high
pressure and
Extreme low
Environment temperature)

Micro-
Gravity Unique Research
(near-zero Tool:
gravity) Trace Fluorescent
Salted Labeling
Complex Media (high
Genome solute
Evolution concentrati
on)

Core Value Core Development Core Product

According to Frost & Sullivan’s research, iXpressGenes is revolutionizing therapeutics design through the discovery of
proteins and enzymes from genomes subjected to extreme environments, which have special qualities that can be used in
synthetic biology approaches to engineering and metabolic reactions.

Source: Frost & Sullivan

8
Leveraging Human Data Science and Advanced Analytics for Clinical
Genomics
IQVIA

Advancing Product Development through Seamless Program Management Platforms

IQVIA works in close partnership with several companies. Charles River is the preferred partner for preclinical/non-clinical
research, while WuXi AppTec and City of Hope are the preferred partners for manufacturing and CMC support.

Overview Key Offerings Genomics England Key Advantages

Collaboration

 IQVIA and Genomics England have End-to-end product development

IQVIA (IMS Health and
Quintiles) is a leading
provider of tech platforms and
contract research services
across the global healthcare
industry. The company’s cell
and gene therapy center
helps advance biotherapeutic
products from candidate
identification through market
authorization. The IQVIA
CORE platform leverages
human data science and
advanced analytics to enable
actionable clinical insights.
IQVIA’s core offerings
recently launched a collaborative platform solutions through a seamless program
across cell and gene to combine robust clinical insights from management platform
therapy include: IQVIA with the world’s largest genomic
 Regulatory Services  Cross functional teams with strategic
database for a wide range of research and
advisory capabilities to drive clinical
 Preclinical/Non- clinical applications, including patient
and commercial success
clinical Research stratification
 Manufacturing/CMC  The collaboration is likely to transform the Access to grant funding sources, for
support future of the global precision medicine up to $15 million
 Asset Development landscape through a user friendly clinical For CIRM applicants and grantees,
genomics platform. IQVIA provides access to grant
Strategy
 This collaboration is already helping a optimization and budget development
 Commercial Services
Japanese pharma company conduct insights, apart from enabling preferred
 Clinical Study precision medicine trials and could be
Conduct pricing and priority status for delivery
transformative for other pharma companies
of grant awards services
as well.

Source: Frost & Sullivan

9
Leveraging Homologous Recombination for Gene Editing
Homology Medicines
Homology Medicines Poised to Transform the Gene Editing and Gene Therapy Landscape through
Natural Homologous Recombination-based Technology
Overview
• Homology Medicines, US, has developed a unique technology
that leverages natural homologous recombination for in vivo
gene editing, and is also capable of in vivo gene therapy
(gene transfer). The company’s unique technology is based
on the new discovery of adeno-associated viral vectors that
have been sourced from hematopoietic human stem cells
(AAVHSCs) to deliver gene therapies. The company has
exclusive access to a varied AAV portfolios for gene therapy
and gene editing applications.
Innovation Attributes
• The technology facilitates high fidelity in in vivo in gene editing
and it does not use nuclease-based gene editing tools, such
as CRISPR or TALENs.
• Homology Medicines’ lead gene therapy candidate, HMI-102,
is currently expected to begin a Phase 1/2 clinical studies for
Phenylketonuria (PKU) in 2019.
• Additionally, the company is also developing a gene editing
candidate for pediatric patients with PKU.
Key Applications
• Homology Medicines has preclinical candidates in
development across the following indications:
• Adult PKU
• Pediatric PKU
• Metachromatic Leukodystrophy
• Hemoglobinopathies
• Opthalmic Indications
Company Highlights
• In November 2017, Homology Medicines partnered with
Novartis for the development of gene editing technology for
hemoglobinopathy (sickle cell disease) and selected
ophthalmic targets.
• In March 2018, Homology Medicines raised an impressive
$166 million (gross) in an initial public offering of stock.
Frost & Sullivan’s Verdict: Post the recent regulatory
approvals, there is surely a growing interest in gene therapy
technologies. Homology’s candidates, if successful, have the
potential to transform the future of genetic medicines.
Source: Frost & Sullivan
10
Advancing the Manufacture of Viral Vectors
Vigene Biosciences

Overview Technology Differentiation

Vigene is a gene therapy company/CDMO that can help gene • Vigene’s value proposition is that they are only focused on
therapy developers from a gene therapy conception stage all the viral vectors and offer unprecedented expertise in that space.
way to the commercialization stage. The company has multiple The company has virologists, biomedical engineers,
business units and offers research grade production for proof-of- mechanical engineers and hence, the company can
concept animal studies. Vigene’s research grade business unit is manufacture viral vectors with high potency and consistency.
the largest commercial company in the world to distribute research The focus and technology capabilities in the viral vector space
grade biovectors. The company is the only licensee for AB is the key competitive differentiation that Vigene has to offer in
Biosciences and is the only distributor for Michael J Fox Foundation the global biomanufacturing landscape.
of Parkinson’s Disease for viral vector research reagents.

Technology Focus Recent Developments

• The company’s key focus • Key Vector Types: • Vigene acquired Omnia Biologics (Rockville) in March 2017 for
areas comprise three • Plasmid, Adenoviral, an undisclosed sum. The purchase also included Omnia’s
areas of viral vector Lentiviral and AAV 7,000-square-feet cGMP facility, which houses three
production: manufacturing suites and a process development laboratory for
• 1) Gene therapy viral vector production.
• Key AAV serotypes: • Vigene Biosciences announced a collaboration with Virovek to
viral vector,
including AAV, • AAV1, AAV2, AAV5, make high yield cGMP AAV production technology accessible
and the lentivirus AAV7, AAV6, AAV8, and affordable.
AAV9 & AAV-DJ
• 2) Viral Vaccine Frost & Sullivan’s Verdict: Vigene has successfully addressed
production key industry challenges related to payload, scalability, and
• 3) Plasmid based • Key Cell Types: flexibility across the global gene therapy CDMO landscape and
is a leader of both research-grade and cGMP-grade AAV,
production • C19, SF9
lentivirus, plasmid, and adenovirus-based production platforms.
Source: Frost & Sullivan

11
Accelerating the Development of Biopharmaceutical Products
Batavia Biosciences

Batavia offers an unprecedented range of technology and services for enabling the development of a
wide range of biopharma candidates.

Overview Recent Developments

• Batavia is working together with Univercells on a project
• Batavia has developed several technologies that help funded by the Gates Foundation to develop a low cost
accelerate product yield and stability, while reducing manufacturing platform that can enable a 10 fold decrease in
development time, risks and costs across the biopharma production costs
manufacturing industry. Batavia seamlessly integrates several • Batavia has collaborated with leading academic institutions
processes such as pool generation, selection of stable clones, and public organizations such as the World Health
stability assessment, bioreactor performance and GMP cell Organization (WHO), Bill & Melinda Gates Foundation
banking to generate high quality stable protein producing cell (BMGF), and the National Institute of Health (NIH) to improve
lines within an impressive timeframe of less than 12 weeks. the health of people around the world.
Technology Focus Company Highlights
• Key Focus Areas: • Batavia Biosciences offers a diverse range of groundbreaking
technologies such as SIDUS®, SCOPE®, SATIRN®, SCOUT®,
• Viral vectors for gene therapy and vaccines
and STEP® for the global biopharmaceutical industry. These
• Non-vector based vaccines (live attenuated or heat
technologies address long-standing challenges related to
killed)
product stability, production yield, and costs.
• Proteins
• Currently, it is working on developing vaccines against polio,
• Antibodies rotavirus, Chikungunya and influenza viruses. Additionally, the
• Microbial proteins company develops virus-neutralizing antibodies for first-line
• Key Cell Types: protection against HIV viruses.
• Viral vectors: HEK293
Frost & Sullivan’s Verdict: Batavia is suitably poised to lead
• Vaccines: Vero the global biopharma manufacturing landscape through
• Proteins: CHO or E.coli differentiated technology and service offerings.
• Bioreactor Scale: Up to 200L
Source: Frost & Sullivan

12
Promising Preclinical Data for off-the-shelf Cell Therapy
Fate Therapeutics, San Diego, CA, US

FT500 is the acronym assigned by Fate Therapeutics for its off-the-shelf immunotherapy for the
treatment of advanced solid tumors. FT500 in combination with an immune checkpoint blocker at the
preclinical investigation stage has shown good results with the company having landed an IND approval
from the FDA.

Overview Preclinical Results

• The FDA has accepted an IND application of Fate
Therapeutics' investigational drug, FT500 for the treatment of
advanced solid tumors following encouraging preclinical
results.
• FT500 is an off-the-shelf investigational cell therapy. If
successful in human trials, it could be the first of its kind.
• The basis for the development of the treatment is that
Improper functioning and low numbers of natural killer (NK)
cells are characteristics of most cancers.
Therapeutic Focus
• The allogenic nature of the cell therapy could mean decreased • Clonal iPSC cell lines were utilized in the production of INK
manufacturing costs as it does not need to be customized for
individual patients unlike the currently approved CAR-T
treatments.
• Checkpoint inhibitory receptor (CIR) therapy such as anti-PD1
antibody is currently used for eliminating tumors but many tumor
subtypes develop resistance and tumor relapses also remain a • Fate Therapeutics is soon expected to begin clinical studies of
cause of concern.
• Large-scale expansion of NK cells was done by differentiation
of induced pluripotent stem cells (iPSCs). The resulting induced
NK (iNK)cells were uniform, homogenous, and well-
characterized.
• In vitro results of 3D spheroid assays indicated the ability of
iNK cells to recruit T cells especially in the presence of K562
cells (Leukemia cell line) and the tumor reduction capacity of:
iNK cells alone- 58%, iNK cells + activated T cells- 71% and
iNK cells + activated T cells + anti-PD-1 Ab- 99%.
• In vivo results: Similar results to the in vitro tests was observed
in the NSG animal models with regard to the ability of iNK cells
to recruit T cells in the presence of K562 cells
Next Steps
cells. It offers a viable solution for mass production, a challenge
usually faced with autologous CAR-T treatments.
• The iNK cells produced from clonal master iPSC cell lines
displayed a high expression of the cytotoxicity molecules,
granzyme B and perforin.
FT500 in combination with CIR therapy for the treatment of
advanced solid tumors evaluating the safety and tolerability of
multiple doses of FT500, in multiple dosing cycles with CIR in
subjects who have both progressed and failed on standalone
CIR therapy.
Source: Frost & Sullivan

13
Tau PET Imaging Tracer, APN-1607 Licensed for Use in Tauopathy Clinical
Studies
APRINOIA Therapeutics, Taipei City, Taiwan

APRINOIA Therapeutics has provided a nonexclusive license to Celgene for the use of the company’s [18F]-labeled
investigational imaging tracer, APN-1607 in Tau PET imaging. APN-1607 was awarded the orphan drug designation
for progressive supranuclear palsy in 2017.
Celgene intends to employ APN-1607 for selection of patient population and measurement of efficacy in its tauopathy
clinical studies globally.

APN-1607
Diagnostic
Imaging

APN-1701 Tau PET Imaging,

Tau inhibitor, & Anti-
Tau Antibody
Therapeutics™ α-synuclein

Product Pipeline Imaging Tracers in Development Therapeutic Focus

Frost & Sullivan’s comments: Celgene’s interest in utilizing APN-1607 indicates the strength of APRINOIA Therapeutics’
technology and the versatile applications of the Taiwan-based company’s imaging tracers in the Tau disease modality.

Source: Frost & Sullivan

14
Prognostic and Diagnostic Cancer Screening Assays
Contextual Genomics, Vancouver, BC, Canada

Contextual Genomics has successfully launched an improved version of its molecular hotspot detection assay
with enhanced mutation detection panel and also a new liquid biopsy assay to help track disease progression.

Find It™ Follow It™ Quality Nexus™

The first version of the Find It
panel was launched in 2016.
The assay has a screening
panel for 146 somatic genome
alterations, and 23 exons in 30
cancer-associated genes. The
molecular hotspot assay would
offer insights, enabling
precision treatment for cancer
patients. For example,
identification of specific gene
mutations can reveal drug
resistance, immunodeficiency
and so on.
The screening panel is similar to the
Find It panel, but the liquid biopsy
assay screens for mutations in the
cell-free circulating tumor DNA found
in blood plasma. While the Find It
panel serves as a preliminary
investigational tool, the Follow It
panel would serve as a monitoring
tool that can highlight tumor burden
and any observed drug resistance. It
can help highlight disease
progression for a better treatment
outcome for patients, especially
ones with metastatic cancers.
The quality control of the next-
generation sequencing assays is
completely automated. The NGS
assays are equipped with the patented
Quality Nexus platform that oversees
computational quality and facilitates
detection of mutations by using a large
number of proprietary molecular
barcodes. The platform also can help
identify true mutations from molecular
diversity indices through a machine
learning approach focused on single
nucleotide variants and molecular
barcoding analysis.

Frost & Sullivan’s Analysis: The next-generation sequencing assays are great point-of-care diagnostic aids that can help patients
receive the best care as they enable doctors to provide a customized treatment approach.

Source: Frost & Sullivan

15
Encouraging Interim Clinical Results of GoCAR-T® Cell Therapy Candidate
Bellicum Pharmaceuticals, Houston, TX, US

Bellicum Pharmaceuticals’ much anticipated GoCAR-T® candidate, BPX-601 has displayed positive initial
results with respect to the safety and activity of the therapy. The therapy is being assessed for its
effectiveness in the treatment of solid tumors.

Disease and Technology Focus Current Clinical Study

• Advanced pancreatic cancer has one of the poorest prognosis
of all cancer types. The emergence of CAR-T therapy provided
hope for a better treatment although not a lot of progress has
been made.
• Bellicum Pharma’s GoCAR-T® technology involved
incorporation of a trigger for T cell proliferation. The trigger is
the presence of an antigen coupled with administration of the
drug, rimiducid.
Medical Need
One of the main undesirable effects of CAR-T cell therapy has
been the unpredictable response and toxicities, such as cytokine
release syndrome (CRS) which can prove fatal if not treated
immediately. To address this concern, a trigger mechanism was
devised (GoCAR-T® technology) to provide physicians greater
control over the proliferation of T cells.
• Study title: A Phase 1/2 Feasibility, Safety, and Activity Study
of PSCA-Specific Chimeric Antigen Receptor Engineered T
Cells (BPX-601) in Subjects
• Study type: Open label, non-randomized, single group
intervention
• Number of Participants: 12
• NCT Number: NCT0274287
• Condition: Pancreatic Adenocarcinoma,
• Phase: 1/2
• Intervention: Biological- BPX-601 & Drug: Rimiducid
• Primary Outcome: Safety and efficacy
• Status: Recruiting
• Intermittent results: Clinical evidence was observed for proper
functioning of GoCAR-T technology in patients. T-cell
proliferation and persistence was witnessed.

Outcome: The treatment control provided by GoCAR-T could possibly provide unique treatment benefits. Solid tumors have
been the most difficult forms of tumors to treat but the GoCAR-T therapy provides encouragement, as the adenocarcinoma
disease modality is in a critical need for better treatments. On the safety aspect of the study, no adverse event was reported,
including no CRS or neurotoxicity that occur as a result of CAR-T cell therapy. Other adverse effects that are experienced by
cancer patients usually undergoing chemotherapy or immunotherapy were observed though.
Source: Frost & Sullivan

16
 Industry Relations

D759-TV 17
Industry Relations
Contact Dashboard

Contact Company/Details

1 Cyrus Biotechnology Dr. Lucas Nivon, CEO. 500 Union St. Suite 320, Seattle, WA 98101.
Phone: +1-206-258-6561. E-mail: lnivon@cyrusbio.com URL: https://cyrusbio.com/

2 Synvivia Gabriel Lopez, Ph.D., CEO, Founder. Address 2341 Grant St Unit B Berkeley, CA 94703-
2570. Phone: +1-571-306-5201. E-mail: glopez@synvivia.com.
URL: https://www.synvivia.com/

3 Elemental Machines John Morgan, Director of Marketing. Salem, New Hampshire, 03079.
Phone: + 1-978-289-7738. E-mail: morgan@elementalmachines.io.
URL: https://elementalmachines.io/

4 iXpressGenes Marc Pusey, Scientist. 601 Genome Way, Huntsville, AL 35806.

Phone: +1-256-327-9452. E-mail: marc.pusey@ixpressgenes.com.
URL: http://www.ixpressgenes.com/

5 IQVIA Tor Constantino, Media Relations, 4820 Emperor Blvd. Durham, NC 27703.
Phone: 484-567-6732. E-mail: tor.constantino@iqvia.com, URL: https://www.iqvia.com/

6 Homology Medicines Theresa McNeely, SVP, Corporate Communications & Patient Advocacy, One Patriots Park,
Bedford, MA 01730. Phone: +1-781-691- 3510. E-mail: tmcneely@homologymedicines.com,
URL: https://www.homologymedicines.com

18
Industry Relations
Contact Dashboard

Contact Company/Details

7 Vigene Biosciences Jeffrey Hung, Chief Commercial Officer, Suite 105, 9430 Key West Ave, Rockville, MD 20850.
Phone: 301-251-6638. E-mail: jhung@vigenebio.com, URL: https://www.vigenebio.com/

8 Batavia Biosciences Bioscience Park Leiden, Zernikedreef 16 2333 CL Leiden, The Netherlands.
URL: https://www.bataviabiosciences.com/

9 Fate Therapeutics Scott Wolchko, President & CEO. 3535 General Atomics Court, Suite 200, San Diego, CA 92121.
Phone: 858-875-1800. E-mail: info@fatetherapeutics.com URL: https://fatetherapeutics.com/

10 Aprinoia Te-Yu Chen, Business Development Associate. 17F, No. 3, Park Street, Nangang District, Taipei
Therapeutics City 11503, Taiwan. Phone: 86-512-8777-8382. E-mail: tychen@aprinoia.com.
URL: https://www.aprinoia.com/

11 Contextual Celia Courchene, President. Suite 204 Donald Rix Building, 2389 Health Sciences Mall,
Genomics Vancouver, BC V6T 1Z3 Canada. E-mail: info@contextualgenomics.com
URL: https://contextualgenomics.com/

12 Bellicum Rick Fair, President & CEO. 2130 West Holcombe Boulevard, Suite 800, Houston, TX 77030.
Pharmaceuticals Phone: 832-384-1100. E-mail: info@bellicum.com URL: http://www.bellicum.com/

19
Regional Practice Leaders and Innovation Experts
Frost & Sullivan Worldwide Experts in Life Sciences Health & Wellness Technology and Market

Frost & Sullivan Experts in the Life Sciences Health & Wellness Industry Covering the Entire Globe
Frost & Sullivan global experts identify emerging and disruptive life sciences, health and wellness technologies, methods,
and processes to develop, acquire or invest. Clients are provided with R&D projects synergy and portfolio management,
serendipitous technology convergence, intelligence strategy for early-mover advantage, product development and
commercialization approach, collaboration and co-creation value enhancement, and strategic decision making solutions.

Rajiv Kumar
Senior Partner and Global Anand S
Vice President Vice President
California, USA Chennai, India

Sudeep Basu, PhD
Practice Leader
Innovation Services
California, USA
Cecilia Van Cauwenberghe, PhD
Senior Industry Analyst
Associate Fellow
Buenos Aires, Argentina
Deepak Jayakumar
Senior Research Analyst
Chennai, India
Vandana Iyer Sudeep Basu, PhD
Senior Research Analyst Global Practice Leader
Chennai, India Innovation Services
Frost & Sullivan, TechVision
Phone: +1 650-776-7413
E-mail: sbasu@frost.com
URL: www.frost.com/techvision

20